Select your country

20.12.2018
STADA’s EUR 300,000,000 1.75% Senior Notes due 2022

STADA’s EUR 300,000,000 1.75% Senior Notes due 2022

STADA and certain of its significant subsidiaries have today granted certain in rem security to secure certain capital markets indebtedness …

Read more

06.12.2018
STADA increases its stake in Pymepharco in Vietnam

STADA increases its stake in Pymepharco in Vietnam

STADA CEO Peter Goldschmidt: "An excellent basis for becoming a key leader in Vietnam"

Read more

28.11.2018
STADA: Completion of the compliance investigation

STADA: Completion of the compliance investigation

No pending or expected legal disputes in relation to former members of the Management Board or employees.

Read more

11.10.2018
STADA WINS GGB18 AWARD

STADA WINS GGB18 AWARD

STADA wins 2018 Global Generics & Biosimilars Award in “Company of the Year, EMEA” category.

Read more

12.09.2018
STADA invites the holders of the STADA Bond to participate in the bondholders‘ meeting

STADA invites the holders of the STADA Bond to participate in the bondholders‘ meeting

Read more

03.09.2018
STADA CEO Peter Goldschmidt

STADA CEO Peter Goldschmidt

Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO

Read more

20.07.2018
STADA Launches Anti-Cancer Drug Pemetrexed

STADA Launches Anti-Cancer Drug Pemetrexed

STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.

Read more

28.06.2018
Strategic expansion of OTC portfolio continues – STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica

Strategic expansion of OTC portfolio continues – STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica

STADA is further strengthening its position in branded over-the-counter healthcare products.

Read more

08.03.2018
STADA records positive business development in 2017

STADA records positive business development in 2017

STADA records positive business development in 2017

Read more

02.03.2018
STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim

STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim

STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim

Read more